Head and Neck Cancer Market: Global Industry Analysis and forecast 2024-2030

Head and Neck Cancer Market is expected to reach USD 3.66 Bn. at a CAGR of 15.23% during the forecast period 2030.

Head and Neck Cancer Market Drivers and Restrains:

Head & neck cancers contain a number of various malignant tumors that grow in or around the throat, larynx, nose, sinuses, lips, salivary glands, and mouth. The current standard of care for head and neck cancer includes surgery, radiation therapy, chemotherapy, and immunotherapy. Although traditional chemotherapeutic drugs first used in combination of radiation therapy, targeted immune therapies are developing as a standard treatment option for advanced-stage head & neck cancers.Head and Neck Cancer MarketTo know about the Research Methodology :- Request Free Sample Report Increase in the patient population, rise in health care infrastructure in developing economies, growth of the pharmaceutical industry, increase in product approvals, rise in government initiatives, surge in research and development activity are driving the head and neck cancer market.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis. Upsurge in consumption of alcohol and tobacco is a main cause of head and neck cancer. As per valued xx% of head and neck cancers is caused due to consumption of alcohol and tobacco. Increase in the number of head and neck cancer patients across the global is expected to drive demand for treatment. Recently, according to the American Society of Clinical Oncology (ASCO), head and neck cancer accounted for almost xx% of all cancers in the U.S. Furthermore, almost xx individuals will develop head and neck cancer in the upcoming period. However, high failure rate of late stage clinical trials and high cost of treatment are restraining the head and neck market growth at global level. Increasing number of new product approvals in the head and neck cancer market is projected to provide lucrative opportunities during the forecast period.

Head and Neck Cancer Market Segmentation Analysis:

Based on the drug class, the head and neck cancer market has been segmented into EFGR inhibitors, Mitotic inhibitors and Anti-PD-a monoclonal antibodies. The anti-PD-1 monoclonal antibodies segment is expected to dominate the head and neck cancer market in 2018, owing to Increase in awareness, rise in demand for efficient drugs for treatment, and new product approvals are expected to drive the segment during the forecast period. Drug class such as anti-PD-1 monoclonal antibodies are regularly used in the treatment of head and neck (HNC) cancer. Such factors are expected to drive the segment during the forecast period like development of new products, rise in mergers & acquisitions, Increase in research and development activity in the pharmaceutical industry. Based on the distribution channel, the head and neck market is classified into hospital pharmacies, drug stores & retail pharmacies, and online stores. The drug stores & retail pharmacies segment is dominated the market in 2018 owing to its higher presence. Furthermore, The online stores segment is expected to grow at the largest CAGR of xx% during the forecast period due to rise in preference for online purchasing of drugs over the traditional methods, increase in number of internet users, and growth in awareness about online pharmacy.

Head and Neck Cancer Market Regional Analysis:

Geographically, the head and neck cancer market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the head and neck cancer market in 2018 owing to increasing acceptance of advanced and high-cost drug therapies, increased treatment rate, and favorable reimbursement policies in the region. Asia-Pacific offerings beneficial growth opportunities for the crucial players operating in the head & neck cancer market owing to large population base, surge in incidence of head & neck cancer, and increase in demand for head & neck cancer combination treatment. The growth in alcohol consumption, increase in cigarette smoking, and higher usage of tobacco are the risk factor, which are expected to fuel the market growth. In Asia Pacific region, Betel quid chewing is the most common form of tobacco chewing. Moreover, increase in awareness toward treatment & early screening of the disease and rise in healthcare expenditure fuel the growth of the market in this region. China and India are highly populated countries with the maximum number of head and neck cancer patients making them major contributor to the growth of the market in Asia Pacific. A report cover the recent development for head and neck market i.e., Recently, Bristol-Myers Squibb Company declared the U.S. Food and Drug Administration (FDA) approval for Opdivo (nivolumab) injection for intravenous use in the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)

Head and Neck Cancer Market Competitive landscape

Major Key players operating in this market are AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, Fortress Biotech, Inc., F. Hoffmann-La Roche Ltd. Manufacturers in the Head and Neck Cancer are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers. The objective of the report is to present comprehensive analysis of market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding market dynamics, structure by analyzing the market segments, and project the market size. Clear representation of competitive analysis of key players by drug class, price, financial position, product portfolio, growth strategies, and regional presence in the market make the report investor’s guide.

Scope of the Head and Neck Cancer Market: Inquire before buying

Global Head and Neck Cancer Market
Report Coverage Details
Base Year: 2023 Forecast Period: 2024-2030
Historical Data: 2018 to 2023 Market Size in 2023: USD 1.35 Bn.
Forecast Period 2024 to 2030 CAGR: 15.23% Market Size in 2030: USD 3.66 Bn.
Segments Covered: by Drug Class EFGR inhibitors Mitotic inhibitors Anti-PD-1 monoclonal antibodies
by Distribution Channel Hospital Pharmacies Drug Stores & Retail Pharmacies Online Stores

Head and Neck Cancer Market, by Region:

North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, Turkey, Russia and Rest of Europe) Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina, Columbia and Rest of South America)

Head and Neck Cancer Market, Key Players are:

1. AstraZeneca PLC 2. Bristol-Myers Squibb Company 3. Eli Lilly and Company 4. Fortress Biotech, Inc. 5. F. Hoffmann-La Roche Ltd. 6. Immutep Limited 7. Merck KGaA 8. Novartis AG 9. Pfizer Inc. 10. Philips Healthcare 11. GE Healthcare 12. Siemens Healthcare 13. Varian Medical Systems 14. Shimadzu Corporation 15. Addent, Inc. 16. Identafi 17. Velscope VX 18. AB Science SA 19. AbbVie Inc.

Frequently Asked questions

1. What is the market size of the Global Head and Neck Cancer Market  in 2023? Ans. The market size Global Head and Neck Cancer Market t in 2023 was USD 1.35 Billion. 2. What are the different segments of the Global Head and Neck Cancer Market ? Ans. The Global Head and Neck Cancer Market  is divided into Drug Class and Distribution Channel. 3. What is the study period of this market? Ans. The Global Head and Neck Cancer Markett will be studied from 2023 to 2030. 4. Which region is expected to hold the highest Global Head and Neck Cancer Market share? Ans. The Asia Pacific dominates the market share in the  market. 5. What  is the Forecast Period of Global Head and Neck Cancer Market ? Ans. The Forecast Period of the market is 2024-2030 in the market.
Head and Neck Cancer Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Head and Neck Cancer Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 4.8. Patent Registration 5. Supply Side and Demand Side Indicators 6. Global Head and Neck Cancer Market Analysis and Forecast 6.1. Global Head and Neck Cancer Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Head and Neck Cancer Market Analysis and Forecast, by Drug Class 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Head and Neck Cancer Market Value Share Analysis, by Drug Class 7.4. Global Head and Neck Cancer Market Size (US$ Bn) Forecast, by Drug Class 7.5. Global Head and Neck Cancer Market Analysis, by Drug Class 7.6. Global Head and Neck Cancer Market Attractiveness Analysis, by Drug Class 8. Global Head and Neck Cancer Market Analysis and Forecast, by Distribution Channel 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Head and Neck Cancer Market Value Share Analysis, by Distribution Channel 8.4. Global Head and Neck Cancer Market Size (US$ Bn) Forecast, by Distribution Channel 8.5. Global Head and Neck Cancer Market Analysis, by Distribution Channel 8.6. Global Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel 9. Global Head and Neck Cancer Market Analysis, by Region 9.1. Global Head and Neck Cancer Market Value Share Analysis, by Region 9.2. Global Head and Neck Cancer Market Size (US$ Bn) Forecast, by Region 9.3. Global Head and Neck Cancer Market Attractiveness Analysis, by Region 10. North America Head and Neck Cancer Market Analysis 10.1. Key Findings 10.2. North America Head and Neck Cancer Market Overview 10.3. North America Head and Neck Cancer Market Value Share Analysis, by Drug Class 10.4. North America Head and Neck Cancer Market Forecast, by Drug Class 10.4.1. EFGR inhibitors 10.4.2. Mitotic inhibitors 10.4.3. Anti-PD-1 monoclonal antibodies 10.5. North America Head and Neck Cancer Market Value Share Analysis, by Distribution Channel 10.6. North America Head and Neck Cancer Market Forecast, by Distribution Channel 10.6.1. Hospital Pharmacies 10.6.2. Drug Stores & Retail Pharmacies 10.6.3. Online Stores 10.7. North America Head and Neck Cancer Market Value Share Analysis, by Country 10.8. North America Head and Neck Cancer Market Forecast, by Country 10.8.1. U.S. 10.8.2. Canada 10.9. North America Head and Neck Cancer Market Analysis, by Country 10.10. U.S. Head and Neck Cancer Market Forecast, by Drug Class 10.10.1. EFGR inhibitors 10.10.2. Mitotic inhibitors 10.10.3. Anti-PD-1 monoclonal antibodies 10.11. U.S. Head and Neck Cancer Market Forecast, by Distribution Channel 10.11.1. Hospital Pharmacies 10.11.2. Drug Stores & Retail Pharmacies 10.11.3. Online Stores 10.12. Canada Head and Neck Cancer Market Forecast, by Drug Class 10.12.1. EFGR inhibitors 10.12.2. Mitotic inhibitors 10.12.3. Anti-PD-1 monoclonal antibodies 10.13. Canada Head and Neck Cancer Market Forecast, by Distribution Channel 10.13.1. Hospital Pharmacies 10.13.2. Drug Stores & Retail Pharmacies 10.13.3. Online Stores 10.14. North America Head and Neck Cancer Market Attractiveness Analysis 10.14.1. By Drug Class 10.14.2. By Distribution Channel 10.15. PEST Analysis 10.16. Key Trends 10.17. Key Development 11. Europe Head and Neck Cancer Market Analysis 11.1. Key Findings 11.2. Europe Head and Neck Cancer Market Overview 11.3. Europe Head and Neck Cancer Market Value Share Analysis, by Drug Class 11.4. Europe Head and Neck Cancer Market Forecast, by Drug Class 11.4.1. EFGR inhibitors 11.4.2. Mitotic inhibitors 11.4.3. Anti-PD-1 monoclonal antibodies 11.5. Europe Head and Neck Cancer Market Value Share Analysis, by Distribution Channel 11.6. Europe Head and Neck Cancer Market Forecast, by Distribution Channel 11.6.1. Hospital Pharmacies 11.6.2. Drug Stores & Retail Pharmacies 11.6.3. Online Stores 11.7. Europe Head and Neck Cancer Market Value Share Analysis, by Country 11.8. Europe Head and Neck Cancer Market Forecast, by Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Rest of Europe 11.9. Europe Head and Neck Cancer Market Analysis, by Country 11.10. Germany Head and Neck Cancer Market Forecast, by Drug Class 11.10.1. EFGR inhibitors 11.10.2. Mitotic inhibitors 11.10.3. Anti-PD-1 monoclonal antibodies 11.11. Germany Head and Neck Cancer Market Forecast, by Distribution Channel 11.11.1. Hospital Pharmacies 11.11.2. Drug Stores & Retail Pharmacies 11.11.3. Online Stores 11.12. U.K. Head and Neck Cancer Market Forecast, by Drug Class 11.12.1. EFGR inhibitors 11.12.2. Mitotic inhibitors 11.12.3. Anti-PD-1 monoclonal antibodies 11.13. U.K. Head and Neck Cancer Market Forecast, by Distribution Channel 11.13.1. Hospital Pharmacies 11.13.2. Drug Stores & Retail Pharmacies 11.13.3. Online Stores 11.14. France Head and Neck Cancer Market Forecast, by Drug Class 11.14.1. EFGR inhibitors 11.14.2. Mitotic inhibitors 11.14.3. Anti-PD-1 monoclonal antibodies 11.15. France Head and Neck Cancer Market Forecast, by Distribution Channel 11.15.1. Hospital Pharmacies 11.15.2. Drug Stores & Retail Pharmacies 11.15.3. Online Stores 11.16. Italy Head and Neck Cancer Market Forecast, by Drug Class 11.16.1. EFGR inhibitors 11.16.2. Mitotic inhibitors 11.16.3. Anti-PD-1 monoclonal antibodies 11.17. Italy Head and Neck Cancer Market Forecast, by Distribution Channel 11.17.1. Hospital Pharmacies 11.17.2. Drug Stores & Retail Pharmacies 11.17.3. Online Stores 11.18. Spain Head and Neck Cancer Market Forecast, by Drug Class 11.18.1. EFGR inhibitors 11.18.2. Mitotic inhibitors 11.18.3. Anti-PD-1 monoclonal antibodies 11.19. Spain Head and Neck Cancer Market Forecast, by Distribution Channel 11.19.1. Hospital Pharmacies 11.19.2. Drug Stores & Retail Pharmacies 11.19.3. Online Stores 11.20. Rest of Europe Head and Neck Cancer Market Forecast, by Drug Class 11.20.1. EFGR inhibitors 11.20.2. Mitotic inhibitors 11.20.3. Anti-PD-1 monoclonal antibodies 11.21. Rest of Europe Head and Neck Cancer Market Forecast, by Distribution Channel 11.21.1. Hospital Pharmacies 11.21.2. Drug Stores & Retail Pharmacies 11.21.3. Online Stores 11.22. Europe Head and Neck Cancer Market Attractiveness Analysis 11.22.1. By Drug Class 11.22.2. By Distribution Channel 11.23. PEST Analysis 11.24. Key Trend 11.25. Key Development 12. Asia Pacific Head and Neck Cancer Market Analysis 12.1. Key Findings 12.2. Asia Pacific Head and Neck Cancer Market Overview 12.3. Asia Pacific Head and Neck Cancer Market Value Share Analysis, by Drug Class 12.4. Asia Pacific Head and Neck Cancer Market Forecast, by Drug Class 12.4.1. EFGR inhibitors 12.4.2. Mitotic inhibitors 12.4.3. Anti-PD-1 monoclonal antibodies 12.5. Asia Pacific Head and Neck Cancer Market Value Share Analysis, by Distribution Channel 12.6. Asia Pacific Head and Neck Cancer Market Forecast, by Distribution Channel 12.6.1. Hospital Pharmacies 12.6.2. Drug Stores & Retail Pharmacies 12.6.3. Online Stores 12.7. Asia Pacific Head and Neck Cancer Market Value Share Analysis, by Country 12.8. Asia Pacific Head and Neck Cancer Market Forecast, by Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. ASEAN 12.8.5. Rest of Asia Pacific 12.9. Asia Pacific Head and Neck Cancer Market Analysis, by Country 12.10. China Head and Neck Cancer Market Forecast, by Drug Class 12.10.1. EFGR inhibitors 12.10.2. Mitotic inhibitors 12.10.3. Anti-PD-1 monoclonal antibodies 12.11. China Head and Neck Cancer Market Forecast, by Distribution Channel 12.11.1. Hospital Pharmacies 12.11.2. Drug Stores & Retail Pharmacies 12.11.3. Online Stores 12.12. India Head and Neck Cancer Market Forecast, by Drug Class 12.12.1. EFGR inhibitors 12.12.2. Mitotic inhibitors 12.12.3. Anti-PD-1 monoclonal antibodies 12.13. India Head and Neck Cancer Market Forecast, by Distribution Channel 12.13.1. Hospital Pharmacies 12.13.2. Drug Stores & Retail Pharmacies 12.13.3. Online Stores 12.14. Japan Head and Neck Cancer Market Forecast, by Drug Class 12.14.1. EFGR inhibitors 12.14.2. Mitotic inhibitors 12.14.3. Anti-PD-1 monoclonal antibodies 12.15. Japan Head and Neck Cancer Market Forecast, by Distribution Channel 12.15.1. Hospital Pharmacies 12.15.2. Drug Stores & Retail Pharmacies 12.15.3. Online Stores 12.16. ASEAN Head and Neck Cancer Market Forecast, by Drug Class 12.16.1. EFGR inhibitors 12.16.2. Mitotic inhibitors 12.16.3. Anti-PD-1 monoclonal antibodies 12.17. ASEAN Head and Neck Cancer Market Forecast, by Distribution Channel 12.17.1. Hospital Pharmacies 12.17.2. Drug Stores & Retail Pharmacies 12.17.3. Online Stores 12.18. Rest of Asia Pacific Head and Neck Cancer Market Forecast, by Drug Class 12.18.1. EFGR inhibitors 12.18.2. Mitotic inhibitors 12.18.3. Anti-PD-1 monoclonal antibodies 12.19. Rest of Asia Pacific Head and Neck Cancer Market Forecast, by Distribution Channel 12.19.1. Hospital Pharmacies 12.19.2. Drug Stores & Retail Pharmacies 12.19.3. Online Stores 12.20. Asia Pacific Head and Neck Cancer Market Attractiveness Analysis 12.20.1. By Drug Class 12.20.2. By Distribution Channel 12.21. PEST Analysis 12.22. Key Trend 12.23. Key Development 13. Middle East & Africa Head and Neck Cancer Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Head and Neck Cancer Market Overview 13.3. Middle East & Africa Head and Neck Cancer Market Value Share Analysis, by Drug Class 13.4. Middle East & Africa Head and Neck Cancer Market Forecast, by Drug Class 13.4.1. EFGR inhibitors 13.4.2. Mitotic inhibitors 13.4.3. Anti-PD-1 monoclonal antibodies 13.5. Middle East & Africa Head and Neck Cancer Market Value Share Analysis, by Distribution Channel 13.6. Middle East & Africa Head and Neck Cancer Market Forecast, by Distribution Channel 13.6.1. Hospital Pharmacies 13.6.2. Drug Stores & Retail Pharmacies 13.6.3. Online Stores 13.7. Middle East & Africa Head and Neck Cancer Market Value Share Analysis, by Country 13.8. Middle East & Africa Head and Neck Cancer Market Forecast, by Country 13.8.1. GCC 13.8.2. South Africa 13.8.3. Rest of Middle East & Africa 13.9. Middle East & Africa Head and Neck Cancer Market Analysis, by Country 13.10. GCC Head and Neck Cancer Market Forecast, by Drug Class 13.10.1. EFGR inhibitors 13.10.2. Mitotic inhibitors 13.10.3. Anti-PD-1 monoclonal antibodies 13.11. GCC Head and Neck Cancer Market Forecast, by Distribution Channel 13.11.1. Hospital Pharmacies 13.11.2. Drug Stores & Retail Pharmacies 13.11.3. Online Stores 13.12. South Africa Head and Neck Cancer Market Forecast, by Drug Class 13.12.1. EFGR inhibitors 13.12.2. Mitotic inhibitors 13.12.3. Anti-PD-1 monoclonal antibodies 13.13. South Africa Head and Neck Cancer Market Forecast, by Distribution Channel 13.13.1. Hospital Pharmacies 13.13.2. Drug Stores & Retail Pharmacies 13.13.3. Online Stores 13.14. Rest of Middle East & Africa Head and Neck Cancer Market Forecast, by Drug Class 13.14.1. EFGR inhibitors 13.14.2. Mitotic inhibitors 13.14.3. Anti-PD-1 monoclonal antibodies 13.15. Rest of Middle East & Africa Head and Neck Cancer Market Forecast, by Distribution Channel 13.15.1. Hospital Pharmacies 13.15.2. Drug Stores & Retail Pharmacies 13.15.3. Online Stores 13.16. Middle East & Africa Head and Neck Cancer Market Attractiveness Analysis 13.16.1. By Drug Class 13.16.2. By Distribution Channel 13.17. PEST Analysis 13.18. Key Trend 13.19. Key Development 14. South America Head and Neck Cancer Market Analysis 14.1. Key Findings 14.2. South America Head and Neck Cancer Market Overview 14.3. South America Head and Neck Cancer Market Value Share Analysis, by Drug Class 14.4. South America Head and Neck Cancer Market Forecast, by Drug Class 14.4.1. EFGR inhibitors 14.4.2. Mitotic inhibitors 14.4.3. Anti-PD-1 monoclonal antibodies 14.5. South America Head and Neck Cancer Market Value Share Analysis, by Distribution Channel 14.6. South America Head and Neck Cancer Market Forecast, by Distribution Channel 14.6.1. Hospital Pharmacies 14.6.2. Drug Stores & Retail Pharmacies 14.6.3. Online Stores 14.7. South America Head and Neck Cancer Market Value Share Analysis, by Country 14.8. South America Head and Neck Cancer Market Forecast, by Country 14.8.1. Brazil 14.8.2. Mexico 14.8.3. Rest of South America 14.9. Brazil Head and Neck Cancer Market Forecast, by Drug Class 14.9.1. EFGR inhibitors 14.9.2. Mitotic inhibitors 14.9.3. Anti-PD-1 monoclonal antibodies 14.10. Brazil Head and Neck Cancer Market Forecast, by Distribution Channel 14.10.1. Hospital Pharmacies 14.10.2. Drug Stores & Retail Pharmacies 14.10.3. Online Stores 14.11. Mexico Head and Neck Cancer Market Forecast, by Drug Class 14.11.1. EFGR inhibitors 14.11.2. Mitotic inhibitors 14.11.3. Anti-PD-1 monoclonal antibodies 14.12. Mexico Head and Neck Cancer Market Forecast, by Distribution Channel 14.12.1. Hospital Pharmacies 14.12.2. Drug Stores & Retail Pharmacies 14.12.3. Online Stores 14.13. Rest of South America Head and Neck Cancer Market Forecast, by Drug Class 14.13.1. EFGR inhibitors 14.13.2. Mitotic inhibitors 14.13.3. Anti-PD-1 monoclonal antibodies 14.14. Rest of South America Head and Neck Cancer Market Forecast, by Distribution Channel 14.14.1. Hospital Pharmacies 14.14.2. Drug Stores & Retail Pharmacies 14.14.3. Online Stores 14.15. South America Head and Neck Cancer Market Attractiveness Analysis 14.15.1. By Drug Class 14.15.2. By Distribution Channel 14.16. PEST Analysis 14.17. Key Trend 14.18. Key Development 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A by Regions, Investment and Applications 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. AstraZeneca PLC 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Product Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Company Footprint 15.3.2. Bristol-Myers Squibb Company 15.3.3. Eli Lilly and Company 15.3.4. Fortress Biotech, Inc. 15.3.5. F. Hoffmann-La Roche Ltd. 15.3.6. Immutep Limited, 15.3.7. Merck & Co., Inc., 15.3.8. Merck KGaA 15.3.9. Novartis AG 15.3.10. Pfizer Inc. 15.3.11. Philips Healthcare 15.3.12. GE Healthcare 15.3.13. Siemens Healthcare 15.3.14. Varian Medical Systems 15.3.15. Shimadzu Corporation 15.3.16. Addent, Inc. 15.3.17. Identafi 15.3.18. Velscope VX 15.3.19. AB Science SA 15.3.20. AbbVie Inc. 15.3.21. Acceleron Pharma, Inc. 15.3.22. ASAHI Roentgen 15.3.23. Astellas Pharma Inc. 16. Primary Key Insights
  • INQUIRE BEFORE BUYING
MMRLogo
America's Fastest Growing Market Research Firm